儿科急诊哮喘就诊时启动吸入性糖皮质激素:一项随机临床试验
该随机试验纳入1至18岁、持续性哮喘且既往未处方控制药物、急诊治疗后离院的儿童。干预组在标准治疗和宣教基础上加用1个月吸入性糖皮质激素处方(按年龄选用氟替卡松或布地奈德)。147名儿童入组,干预组53.5%患者配取了急诊初始吸入性糖皮质激素处方;两组后续基层医生处方配取率无重要差异(干预组21% vs 对照组17%;相对率=1.24;95%CI 0.63至2.41)。急诊后2周内,干预组报告清醒时气短和睡眠中咳嗽减少,但两组在基层医生随访率、功能受限、哮喘相关症状和生活质量方面无差异。
要点
- 儿科急诊哮喘离院时开具吸入性糖皮质激素,未能提高后续基层医生处方配取率(干预组21% vs 对照组17%;相对率=1.24;95%CI 0.63至2.41)。
- 干预组仅53.5%患者配取了急诊开具的初始吸入性糖皮质激素处方。
- 急诊后2周内,干预组报告清醒时气短和睡眠中咳嗽较对照组减少。
- 两组在基层医生随访率、功能受限、哮喘相关症状和生活质量方面无差异。
- 纳入人群为1至18岁持续性哮喘、既往未处方控制药物、急诊治疗后离院的儿童。
适用人群与场景
- 1至18岁持续性哮喘儿童,既往未处方控制药物,急诊哮喘治疗后离院者。
处置流程与药物剂量
- 干预组在标准哮喘治疗和所有患者均接受的宣教基础上,接受1个月吸入性糖皮质激素处方(按年龄选用氟替卡松或布地奈德)。
研究设计与关键结果
- 随机试验纳入147名儿童,基线指标组间相似。
- 干预组53.5%患者配取了急诊初始吸入性糖皮质激素处方。
- 后续基层医生处方配取率:干预组21% vs 对照组17%;相对率=1.24;95%CI 0.63至2.41。
- 急诊后2周内,干预组报告清醒时气短和睡眠中咳嗽较对照组减少。
- 两组在基层医生随访率、功能受限、哮喘相关症状和生活质量方面无差异。
证据类型、等级与局限
- 证据类型:随机临床试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 儿科急诊哮喘离院时开具吸入性糖皮质激素未能提高后续基层医生处方配取率,但可能与2周内清醒时气短和睡眠中咳嗽减少相关。
- 该干预未影响基层医生随访率、功能受限、哮喘相关症状和生活质量。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
STUDY OBJECTIVE: We determine whether prescribing an inhaled corticosteroid during a pediatric emergency department (ED) asthma visit increases ongoing use and improves outcomes.
METHODS: This randomized trial enrolled children aged 1 to 18 years, with persistent asthma not previously prescribed a controller medication, and who were being discharged after ED asthma treatment. Intervention subjects received a 1-month prescription for an inhaled corticosteroid (fluticasone or budesonide by age) in addition to standard asthma therapy and instructions given to all patients. Outcomes included filling of the intervention and subsequent inhaled corticosteroid prescriptions, asthma-related symptoms and quality of life, and follow-up rates with a primary care provider. Outcomes were assessed during telephone interviews 2 and 8 weeks after the ED visit and by review of primary care provider and pharmacy records.
RESULTS: One hundred forty-seven children were enrolled, and baseline measures were similar between groups. In the intervention group, 53.5% of patients filled an initial ED prescription for inhaled corticosteroid. There was no important difference between groups in subsequent filling of a primary care provider prescription (21% intervention versus 17% control; relative rate=1.24; 95% confidence interval 0.63 to 2.41). During the 2 weeks after the ED visit, intervention subjects reported reduced shortness of breath while awake and cough while asleep compared with controls. Groups did not differ by rates of primary care provider follow-up, functional limitations, or asthma-related symptoms and quality of life.
CONCLUSION: There was no difference in the proportion of patients who filled a primary care provider prescription after ED initiation of an inhaled corticosteroid. The intervention was associated with reduced reported symptoms but did not affect other asthma outcomes or primary care provider follow-up.
参考来源
- Sampayo EM, Mazer-Amirshahi M, Camp EA, et al. Initiation of an Inhaled Corticosteroid During a Pediatric Emergency Visit for Asthma: A Randomized Clinical Trial. Ann Emerg Med. 2017. PMID: 28262319. doi:10.1016/j.annemergmed.2017.01.005
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。